{"url_path":"/sec/qncx/proxy/2026-04-27/000119312526182267","section_key":"body","section_title":"DEFA14A body","topic":"sec","document":{"doc_type":"DEFA14A","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-182267-index.html","accession_number":"0001193125-26-182267","cik":"0001662774","ticker":"QNCX","issuer_name":"Quince Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-182267-index.html","primary_entity_key":"0001662774","primary_entity_name":"Quince Therapeutics, Inc."},"word_count":137,"has_tables":true,"body_markdown":"DEFA14A\n\nfalse0001662774DEFA14A00016627742025-01-012025-12-31\n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nSCHEDULE 14A\n\nProxy Statement Pursuant to Section 14(a) of\n\nthe Securities Exchange Act of 1934 (Amendment No.  )\n\nFiled by the Registrant x\n\nFiled by a Party other than the Registrant o\n\nCheck the appropriate box:\n\no\n\nPreliminary Proxy Statement\n\no\n\nConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))\n\no\n\nDefinitive Proxy Statement\n\nx\n\nDefinitive Additional Materials\n\no\n\nSoliciting Material under §240.14a-12\n\nQUINCE THERAPEUTICS, INC.\n\n(Name of Registrant as Specified In Its Charter)\n\n(Name of Person(s) Filing Proxy Statement, if other than the Registrant)\n\nPayment of Filing Fee (Check all boxes that apply):\n\nx\n\nNo fee required\n\n \n\n \n\no\n\nFee paid previously with preliminary materials\n\n \n\n \n\no\n\nFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11"}